A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants

NCT07051993 ↗

Phase 1 Completed 18 enrolled Genentech, Inc.

NaSingle-groupOpen-labelBasic science

Summary

This is a Phase 1, open-label, randomized, two-part study to evaluate the relative bioavailability (rBA) of two tablet formulations compared to the capsule formulation of ZN-A-1041 (Part 1). Part 2 of the study will evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation. No participants were enrolled in Part 2 of the study as it has been cancelled.

Timeline

Start: 2025-06-27
Primary completion: 2025-07-12
Completion: 2025-07-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZN-A-1041	Unknown	—	Oral

Indications

No indication recorded.